MannKind Corporation is a biopharmaceutical company focused on developing and commercializing inhaled therapeutic products and devices for endocrine and orphan lung diseases. The company's proprietary Technosphere dry-powder formulation and Dreamboat inhaler underpin its pipeline. Its commercial portfolio includes Afrezza, an ultra-rapid-acting inhaled insulin; Furoscix, an on-body and injectable furosemide treatment for fluid overload in heart failure; and V-Go, a wearable insulin delivery device. MannKind also manufactures Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease under a partnership with United Therapeutics. Investors follow the stock for its diversified revenue base, growing royalty and manufacturing income, and its advancing dry-powder pipeline in idiopathic pulmonary fibrosis. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, MNKD shares climbed from a closing price of approximately $3.05 on October 21, 2026 to $3.85 on November 20, 2026, a gain of roughly 26%. The move was driven primarily by a strong earnings report and accelerating commercial momentum.
The broader quarterly picture has been more uneven. The stock traded in a wide range between roughly $3.00 and $4.25 during the trailing three months, dipping to a mid-October low near $3.02 before rebounding sharply into early November and then pulling back modestly from an early-November peak near $4.23. While the shares are higher versus the start of the period, nearly all of the net advance occurred in the most recent month, reflecting a shift from range-bound trading to a clearer upward trend.
The primary catalyst was MannKind's third-quarter 2026 earnings release. Total revenue grew 24% year over year to $101.9 million, while commercial product revenue roughly doubled to $45 million as Furoscix and Afrezza became the company's largest revenue source. The Furoscix ReadyFlow autoinjector launch exceeded internal expectations, with roughly 75% of Furoscix shipments converting to ReadyFlow within about six weeks of launch. The pediatric Afrezza launch also outperformed forecasts, with pediatric patients representing about one in four Afrezza prescriptions and new-to-brand prescriptions up nearly 80% sequentially.
Pipeline progress added further support. The company reported positive Phase 1b results for its nintedanib DPI program (MNKD-201), demonstrating favorable safety and tolerability in patients with idiopathic pulmonary fibrosis. A $50 million private placement led by Frazier Life Sciences, which funded the contingent value right payment triggered by ReadyFlow approval, signaled institutional endorsement. Separately, stronger quarterly results and a litigation settlement involving its partner United Therapeutics (UTHR) reinforced confidence in Tyvaso DPI demand, a meaningful source of MannKind's royalties and manufacturing revenue. From what I see, this combination of commercial traction and pipeline data explains much of the recent move.
Over the trailing quarter, MannKind's stock reflected a transition from execution of milestones to early commercial results. The company delivered multiple catalysts earlier in 2026, including the FDA approval of Furoscix ReadyFlow and the pediatric Afrezza indication. The quarter was defined by investors assessing whether those launches would translate into durable revenue growth. Furoscix ReadyFlow's faster-than-expected conversion, combined with reacceleration in Afrezza prescriptions, provided evidence of commercial traction. Meanwhile, management's guidance for fourth-quarter profitability and 2027 full-year profitability offered a clearer financial trajectory, shifting the narrative from a development-stage story toward a diversified, growth-oriented commercial business.
Looking ahead, investors are likely to monitor continued Furoscix ReadyFlow adoption, including conversion trends, prescriber growth, and integration into health systems. Afrezza's pediatric launch and any reacceleration of the adult franchise will be closely watched, given management's expectation that the brand returns to growth in 2027. Confirmation of fourth-quarter 2026 profitability and progress toward 2027 annual profitability are central to the near-term narrative. On the pipeline front, the Phase 2 nintedanib DPI program and potential milestones tied to ralinepag DPI in 2027 represent longer-dated catalysts. Macroeconomic factors, healthcare policy, and competitive dynamics in diabetes and heart failure could also influence sentiment. These are observations of known catalysts and risks, not investment recommendations. I’m watching this closely as the commercial metrics evolve.
In my own research, I often turn to Tickeron’s Trending AI Robots page to see how automated strategies are performing across different market conditions. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies are featured here. The bots vary widely in approach, timeframe, and performance metrics, allowing users to compare different automated strategies. For traders seeking a data-driven, systematic complement to their own research, exploring this page can provide additional perspective on momentum and signals. This has been a useful way for me to cross-check ideas without replacing core fundamental analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MNKD advanced for three days, in 203 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
MNKD moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MNKD crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 143 of 190 cases where MNKD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The 10-day RSI Indicator for MNKD moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 16 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 58 cases where MNKD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MNKD as a result. In 74 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for MNKD turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 38 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
MNKD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-18.662) is normal, around the industry mean (3.596). P/E Ratio (-26.000) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (2.832) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MNKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapeutic products
Industry Biotechnology